Treatment of type 2 diabetic patients with kidney disease with AT1-receptor antagonists: Lessons from recent trials

Clinical and Experimental Nephrology

Volumn 6, Issue 4, 2002, Pages 175-181

  Keane, William F ^a   Kurokawa, Kiyoshi ^b   Lyle, Paulette A ^a   Shahinfar, Shahnaz ^a   Smith, Thomas P ^a   Wieland, Kenneth K ^a   Brenner, Barry M ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

IDNT; LIFE; Nephropathy; RENAAL; Risk factors; Type 2 diabetes

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PROTEINURIA; REVIEW; RISK ASSESSMENT;

EID: 0036965293     PISSN: 13421751     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101570200031     Document Type: Review

References (19)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;14(Suppl 5):S1-85.
2. Makino H. Overview. Why is diabetic nephropathy a problem? Diabetic nephropathy: development, progression, and treatment. Shindann to Chiryousya: Tokyo, 1999;1-4.
3. US Renal Data System. USRDS 1998 Annual Data Report. Bethesda, National Institutes of Health National Institute of Diabetes, 1998.
4. Pastan S, Bailey J. Dialysis therapy. N Engl J Med 1998;338:1428-37.
5. Usami T, Koyama K, Takeuchi O, Morozumi K, Kimura G. Regional variations in the incidence of end-stage renal failure in Japan. JAMA 2000;284:2622-4.
6. Morrish NJ, Wang S, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Survey of Vascular Diseases in Diabetes. Diabetologia 2001;44(Suppl 2):14-21.
7. Lewis EJ, Hunsicker LB, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
8. Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type 2 diabetic patients. Ann Intern Med 1993;118:577-81.
9. Lebovitz HE, Weigmann TB, Cnaan A, et al. Renal protection effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int 1994;Suppl 45:S150-5.
10. Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-50.
11. Taguma Y, Kitamoto Y, Futaki G, et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985;313:1617-20.
12. The UKPDS Study group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS. BMJ 1998;338:703-13.
13. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
14. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
15. Lewis EJ, Hunsicker LG, CLarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
16. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
17. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.
18. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
19. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.